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1. Introduction 
This chapter is focused on the putative role of neurotensin in the development of 
Parkinson’s disease, a neurodegenerative disorder mainly characterized by a progressive 
loss of nigrostriatal dopaminergic neurons (Schimpff et al., 2001). Although a direct causal 
role of neurotensin in Parkinson’s disease has not yet clearly demonstrated, some 
convincing animal and human studies support the potential role of the peptide in the 
etiopathogenesis of this motor disorder. Special emphasis is placed on the significance that 
neurotensin plays on basal ganglia neuroplasticity and neurodegeneration. This is mainly 
supported by recent findings clearly demonstrating that neurotensin enhances glutamate 
excitotoxicity in mesencephalic dopamine neurons and that neurotensin receptors are 
involved in the modulation of NMDA-induced excitotoxicity (Antonelli et al., 2002; 2004). 
Through these mechanisms neurotensin could contribute to the development and/or the 
progression of neurodegenerative disorders. The possible use of neurotensin receptor 
antagonists, in combination with conventional therapy, in the treatment of Parkinson’s 
disease, is also discussed. 
2. Basal ganglia 
In Parkinson’s disease, the degeneration of dopaminergic neurons in the substantia nigra 
pars compacta and the consequent striatal dopamine deficiency lead to a cascade of 
functional modifications in the activity of the basal ganglia-thalamocortical motor circuit, 
responsible for the motor disturbances characteristic of the pathology (Silkis, 2001). The 
basal ganglia are a collective group of structures, which include the neostriatum (caudate 
nucleus and putamen), the external and internal parts of the globus pallidus, the subthalamic 
nucleus, the substantia nigra pars reticulata and the substantia nigra pars compacta.  
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From a simplistic point of view, motor information coming from glutamatergic neurons 
located in several areas of the cerebral cortex, reach the striatum, which represents the 
primary input nucleus of the basal ganglia. These information, processed in the striatum, are 
transmitted by the so called “direct” and “indirect” pathways, to the main output nuclei of 
the basal ganglia (substantia nigra pars reticulata and the internal part of the globus 
pallidus; Fig. 1). The “indirect pathway” encompasses a trisynaptic link including i) 
GABAergic/enkephalinergic neurons, which connect the striatum to the external part of the 
globus pallidus; ii) the external part of the globus pallidus GABAergic neurons projecting to 
subthalamic nucleus and iii) glutamatergic subthalamic nucleus neurons, which project to 
the basal ganglia output structures (internal part of the globus pallidus/substantia nigra 
pars reticulata) and send collaterals to external part of the globus pallidus (Gerfen, 1992). On 
the other hand, the “direct” monosynaptic pathway consists of GABAergic neurons which 
directly connect the striatum to the main basal ganglia output structures (substantia nigra 
pars reticulata and the internal part of the globus pallidus). Outputs from these nuclei 
consist of inhibitory GABAergic neurons projecting to the ventral-anterior and ventrolateral 
nuclei of the thalamus which, through excitatory glutamatergic fibers, project back to the 
prefrontal and motor cortices. The differences in neuronal connectivity between the “direct” 
and “indirect” pathways show dissimilar functional consequences: the stimulation of the 
“direct pathway” inhibits substantia nigra pars reticulata and the internal part of the globus 
pallidus activity, thus leading to a disinhibition of thalamocortical neurons and a 
consequent facilitation of motor initiation. On the contrary, the stimulation of the “indirect 
pathway” produces motor inhibition. In spite of the model of the “direct” and “indirect” 
pathways is an oversimplification of the basal ganglia organization, it still represents the 
cornerstone for modern research on the basal ganglia functions (for review, Smith and 
Villalba, 2008).  
Dopamine released by terminals of neurons located in substantia nigra pars compacta 
markedly affects the functional activity of the striatum. In the striatum dopamine D1 and D2 
receptor subtypes are respectively expressed on the “direct” and “indirect” striatonigral 
pathways and modulate motor information (Gerfen, 2003). Although the degree of this 
anatomical separation of D1 and D2 receptors has been for a time a controversial topic, recent 
studies, using transgenic mice have confirmed that dopamine receptor subtypes have 
mainly a different expression on separate populations of GABAergic medium-spiny 
projection neurons (Wang et al., 2006; Galvan and Wichmann, 2008). Due to the different 
location of its receptor subtypes, striatal dopamine physiologically activates the “direct 
pathway” (D1 receptors) and inhibits the “indirect pathway” (D2), leading to an increase of 
thalamocortical motor drive (see above). In addition, striatal glutamate release from 
corticostriatal glutamatergic terminals is tonically inhibited by dopaminergic input coming 
from the substantia nigra pars compacta and activating dopamine D2 heteroreceptors 
(Bamford et al., 2004). In this synaptic arrangement, dopamine depletion within the striatum 
not only removes tonic dopamine inhibitory control over corticostriatal glutamatergic drive, 
but also induces an imbalance between the “direct” and the “indirect” pathways (Fig. 1). In 
particular, this deficit produces an overactivity of the GABAergic projections from the 
striatum to the external part of the globus pallidus, leading to an excessive inhibition of 
thalamocortical and brainstem motor systems. From a pathological point of view, the 
hyperactivity of striatopallidal GABAergic neurons is considered one of the anomaly 
responsible for generation of motor parkinsonian symptoms. Pharmacological interventions 
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Fig. 1. The changes in the activity of basal ganglia circuits in normal state (’GO’) vs 
Parkinson’s Disease (’NO GO’) are indicated. Heavy arrows, high activity; thin arrows, low 
activity. Abbreviations used: GPl, globus pallidus, lateral; GPm, globus pallidus, medial; 
SNC, Substantia nigra, zona compacta; SNR,Substantia nigra, zona reticulata; SupCol, 
Superior colliculus; Form Ret, formatio retucularis; PPN, Pedunculo pontine nucleus (from 
Tanganelli et al., 2004). 
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that can compensate for loss of dopamine and suppress the expression of motor symptoms 
in the pre-motor stages of Parkinson’s disease are represented by the reduction of: i) the 
excitatory corticostriatal inputs that excite striatal output neurons of the “indirect pathway” 
or ii) the overactivity of striato-pallidal GABAergic neurons. The use of selective D2 receptor 
agonist, A2A adenosine receptor antagonism, blockade of GABA receptors in the external 
part of the globus pallidus or reduction of the excitatory NMDA receptor-mediated 
corticostriatal inputs, impinging upon striatal output neurons of the “indirect pathway”, can 
be helpful for slowing progression of Parkinson’s disease symptoms. 
3. Neurotensin and its receptors  
Neuropeptides represent undoubtedly one of the most common signaling molecules in the 
central nervous system. Accumulating evidence have implicated a vast number of 
neuropeptides and their receptors in the control of a wide range of physiological functions 
and pathological events, including neurodegenerative disorders.  
Like all neuropeptides, neurotensin, an endogenous 13 amino acid peptide (Figure 2), is 
synthesized as part of a larger inactive precursor (Proneurotensin/neuromedin N).  
 
 
Fig. 2. Sequence of neurotensin (modified from Ferraro et al., 2009). 
The precursor molecule, a highly conserved polypeptide of 169-170 amino acid, contains one 
copy each of neurotensin and neuromedin N near the C-terminus and undergoes a 
differential tissue-specific cleavage at its four dibasic sites by proprotein convertases. Pro-
neurotensin/neuromedin N may therefore be processed to generate different sets of 
peptides. Four biologically active products of Pro-neurotensin/neuromedin N processing 
have been described: neurotensin, neuromedin N, large neurotensin and large neuromedin 
N (Kitabgi, 2010). In the brain, Pro-neurotensin/neuromedin N processing mainly depends 
on proprotein convertase 2 activity and leads to high amounts of neurotensin and 
neuromedin N and small quantities of large neurotensin and large neuromedin N (Kitabgi, 
2010). Using radioimmunoassay techniques, it has been demonstrated that the regional 
distribution of neurotensin and neuromedin N in brain tissues is, generally, the same. 
However, marked differences in the ratio of neurotensin over neuromedin N have been 
observed in different brain areas, being neurotensin generally more abundant in 
dopaminergic region such as substantia nigra pars compacta and ventral tegmental area. 
Once processed as an active peptide in neurons, neurotensin is stored in dense core vesicles. 
The physiological inactivation of neurotensin is operated by endopeptidases belonging to 
the family of metallopeptidases, which act on primary cleavage sites in the peptide 
sequence: Arg8-Arg9, Pro10-Tyr11 and Tyr11-Ile12 bonds. Another mechanism that 
produces an inactivation of neurotensin transmission is the process of neurotensin 
internalization.  
Neurotensin is widely expressed in nerve cells, fibers and terminals (Uhl, 1982; Emson et al., 
1985) and exhibits diverse biological actions in the regulation of central nervous system 
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functions of mammals, including man. The peptide is also highly expressed in the 
periphery, where it mainly acts as a modulator of the gastrointestinal and cardiovascular 
systems (Wang and Evers, 1999). Neurotensin was originally isolated and sequenced from 
bovine hypothalamus (Carraway and Leeman, 1973). Subsequent anatomical and functional 
studies have provided evidence that, in the brain, neurotensin behaves as neurotransmitter 
and/or neuromodulator (Nemeroff and Cain, 1985; Mendez et al., 1997). Neurotensin is 
released by neurons through sodium and calcium-dependent mechanisms. Once released, 
neurotensin produces its biological effects by interacting with three different receptor 
subtypes (NTS1, NTS2 and NTS3/sortilin). The large distribution in the central nervous 
system of this family of membrane receptors explains the wide range of physiologic and 
pathologic effects mediated by the neuropeptide (Barroso et al., 2000). NTS1 and NTS2 
receptors belong to the family of G-protein-coupled receptors with seven transmembrane 
domains, which share 60% homology. The NTS1 receptor displays a high affinity for 
neurotensin, while NTS2 receptor has a substantially lower affinity for the peptide and a 
high affinity to levocabastine, a histamine H1 receptor antagonist (Chalon et al., 1996; 
Vincent et al., 1999). NTS3/sortilin receptor is a single transmembrane protein located in 
intracellular vesicles of neurons and glia and appears involved in cell sorting and in tropism 
in cancer cells (Nouel et al., 1999; Mazella et al., 1998). NTS1 receptor is coupled to a variety 
of signaling cascades, including production of inositol phosphates through activation of 
phospholipase C, formation of cAMP and cGMP, and induction of mitogen-activated 
protein kinase phosphorylation. Autoradiographic ligand binding, in situ hybridization, and 
immunohistochemical studies have yielded abundant information on the distribution of 
NTS1 receptors in mammalian brain. NTS1 receptors are markedly expressed in brain 
regions rich in dopamine cell bodies, such as the substantia nigra pars reticulata and pars 
compacta, the ventral tegmental area, and in projection areas of both nigrostriatal and 
mesocorticolimbic dopaminergic pathways, such as striatum, nucleus accumbens and 
frontal cortex (Palacios and Kuhar, 1981; Goulet et al., 1999; Boudin et al., 1998; Binder et al., 
2001). In the striatum and nucleus accumbens, NTS1 receptors are co-localized at post-
synaptic level with dopamine D2 receptors and, although in low density, at the pre-synaptic 
levels too (Pickel et al., 2001; Delle Donne et al., 2004). This receptor co-distribution together 
with the demonstration that neurotensin is localized within the nigrostriatal and mesolimbic 
dopamine neurons explain the role that the neuropeptide plays in the modulation of 
dopamine neurotransmission (Jennes et al., 1982). It is worth noting that in the striatum, 
NTS1 receptors are significantly located on cortical glutamatergic terminals as well as on the 
striatopallidal GABA neurons (Boudin et al., 1996; Alexander and Leeman, 1998; Tanji et al., 
1999). Finally, in the globus pallidus, neurotensin receptors (NTS1 and NTS2) exist in 
different neurons and are located both pre-synaptically and post-synaptically (Fassio et al., 
2000; Sarret et al., 2003) thus regulating (mainly NTS1 receptors), both pallidal glutamatergic 
and GABAergic transmission (Chen et al., 2004; 2006). Such distribution of NTS1 receptors 
justifies the modulation that neurotensin exerts on the mesolimbic, mesocortical and 
nigrostriatal dopamine neurons, as well as on glutamatergic and GABAergic neurones 
(Deutch and Zahm, 1992; Fuxe et al., 1992 a,b; Rostene et al., 1992; Binder et al., 2001; Dobner 
et al., 2003; Petrie  et al., 2005). Most of the central and peripheral functions controlled by 
NTS1 receptors have been elucidated by the use of the non-peptide neurotensin antagonist 
SR48692, which preferentially binds NTS1 receptors (Gully et al., 1993; Rostene et al., 1997).  
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4. Neurotensin levels, neurotensin binding sites and Parkinson’s disease 
The high concentrations of neurotensin in brain regions associated with dopaminergic cell 
bodies and projections, such as the striatum, substantia nigra, ventral tegmental area and 
globus pallidus (for a review, see Binder et al., 2001) indicate that neurotensin and 
dopamine are closely linked. In particular, the influence of neurotensin on nigrostriatal 
and mesocorticolimbic dopaminergic systems suggests that neurotensin may play a 
relevant role in dopamine-associated pathologies, such as some neurodegenerative 
disorders and neuropsychiatric diseases (Rostene et al., 1992; Lambert et al., 1995; St-
Gelais et al., 2006).  
In the following part of this section, data obtained from human and animal studies 
providing the existence of relationships between neurotensin and neurodegenerative 
disorders, will be shortly summarized.  
Numerous studies have tried to determine whether, in humans, changes in the 
neurotensinergic system could be associated to Parkinson’s disease. In an early study, high 
levels of neurotensin-like immunoreactivity were detected in lumbar cerebrospinal fluid 
from Parkinson’s disease patients, whilst no significant changes in neurotensin content were 
observed (Emson et al., 1985). Successively, Fernandez et al. (1995, 1996) found that in post-
mortem samples from basal ganglia of Parkinson’s disease patients there were changes in 
the levels of different neuropeptides. In particular, substantia nigra neurotensin levels were 
two-fold higher in Parkinson’s disease patients than in healthy subjects. It is worth noting 
that in incidental Lewy body disease, which is considered as a pre-symptomatic phase of 
Parkinson’s disease, neurotensin levels tended to increase as in parkinsonian patients, even 
if this increase was not statistically significant (Fearnley and Lees, 1991). Similarly, in 6-
hydroxydopamine-lesioned rats or in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated 
monkeys, two well-characterized animal models of Parkinson’s disease, an increase in 
striatal and globus pallidus neurotensin levels was found, and such an enhancement was 
not modified by L-dopa treatment. In view of the above results, the authors suggested that 
changes in neurotensin levels and other neuropeptides may be considered as an early 
component of an integral part of the pathology rather than a secondary biochemical 
alteration resulting from loss of the nigrostriatal pathway or a drug-induced event. 
However, in contrast to the above results, in a previous study, Taylor et al. (1992) showed 
that substantia nigra neurotensin levels were unchanged following 6-hydroxydopamine 
lesion, but increased by a prolonged treatment with L-dopa. The authors concluded that 
changes in neurotensin levels appear to be only a secondary event, due to dopamine neuron 
loss in combination with protracted drug therapy. Despite these contrasting results, the 
hypothesis that an enhancement of neurotensin levels, associated to an activation of NTS1 
receptor located on the nigral dopamine neurons, contributes to the degeneration of these 
dopamine cells in Parkinson’s disease, is supported by other animals studies. In particular, 
these findings indicate that a neurotensin-induced increase in both striatal and cortical 
endogenous glutamate release, is significantly coupled to an enhancement of neuronal 
excitotoxicity, which can contribute to nigral dopamine cell loss. In addition, it has been 
demonstrated that the neuropeptide increases the energy demands due to an increased 
firing rate in the dopamine cells. These enhancements are, at least in part, caused by a 
reduction of the D2 autoreceptor signaling via an antagonistic NTS1/D2 receptor interaction 
(Fuxe et al., 1992a). These neurochemical and morphological results will be carefully 
described in the subsequent sections (5 and 6).  
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Besides the changes in neurotensin levels, biochemical and histological investigations in post-
mortem brain tissues of parkinsonian patients have shown a significant reduction of 
neurotensin-binding sites in several specific brain areas of the basal ganglia as respect to 
healthy subjects (Chinaglia et al. 1990; Fernandez et al., 1994). In particular, Chinaglia et al. 
(1990), using a receptor autoradiography technique, compared the distribution of neurotensin 
receptors in post-mortem brain tissues from parkinsonian patients, with that found in patients 
affected by progressive supranuclear palsy and-in age-matched controls. Significant decreases 
in neurotensin receptor density were found in the substantia nigra, caudate nucleus, putamen 
and globus pallidus of both groups of patients in comparison to healthy subjects. In addition, a 
significant decrement of neurotensin receptor density was found in the ventral tegmental area, 
nucleus accumbens and dorsal part of caudate in patients with Parkinson’s disease as regards 
to patients with progressive supranuclear palsy, indicating differential involvement of 
neurotensin receptor alterations in these two neurological disorders. Interestingly, in this 
cohort of Parkinson’s disease patients, the reduction of striatal neurotensin binding sites was 
lower than the decrease of dopamine content in this nucleus, suggesting only a partial 
localization of neurotensin receptors on nigrostriatal dopaminergic projections. Using in situ 
hybridization, it has been possible to more specifically illustrate that NTS1 receptor mRNA 
levels were decreased in the substantia nigra of patients with parkinsonism (Yamada and 
Richelson, 1995). These human results were confirmed in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated monkeys, where a decrease in the number of neurotensin-binding 
sites in the striatum and substantia nigra was found (Goulet et al., 1999; Tanji et al., 1999). The 
reduction of NTS1 receptors in the substantia nigra of parkinsonian patients might be related 
to the loss of the nigrostriatal dopaminergic neurons. In contrast, the interpretation of the 
decrease in neurotensin-binding sites observed in the striatum of Parkinson’s disease patients 
is certainly more difficult since, at present, the results concerning the pre-synaptic or the post-
synaptic localization of striatal neurotensin receptors are still contradictory (Quirion et al., 
1985; Cadet, 1991). However, it may be suggested that the decrease in striatal neurotensin-
binding sites may reflect the loss of neurotensin receptors not only on dopaminergic 
nigrostriatal terminals but also on striatal GABAergic medium spiny neurons.  
Taken together, the above mentioned studies from Parkinson’s disease patients suggest a 
significant relationship between the alteration of neurotensinergic system and Parkinson’s 
disease. On the basis of these findings, Schimpff et al. (2001) evaluated whether plasma 
neurotensin concentrations in parkinsonian patients could be considered as a marker in 
diagnosis and severity of this motor disorder. The results emerging from this study showed 
that the plasma neurotensin concentrations were significantly higher in Parkinson’s disease 
patients than in healthy controls. Accordingly, neurotensin concentration in the plasma of 
untreated patients was higher than that observed in treated patients. It is worth noting that 
these findings were compatible with the enhancement of neurotensin levels detected in 
post-mortem brain tissues from parkinsonian patients and data obtained from animal 
studies. Thus, the authors concluded that in addition to the diagnostic criteria for 
Parkinson’s disease “measurement of extracted plasma neurotensin concentrations in patients with 
Parkinson may prove useful as an index in diagnosis”. 
In summary, it can be concluded that the increase in striatal and nigral neurotensin tissue 
concentrations, as well as in cerebrospinal fluid and plasma levels may be due either to a 
loss of dopamine neurons and/or to a dysregulation of neurotensin transmission on striatal 
output, favoring the striatopallidal GABAergic pathway. Further work is needed to better 
understand the role of neurotensin in the pathophysiology of Parkinson’s disease. 
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5. Striatal neurotensin and Parkinson’s disease: neurochemical animal 
studies 
5.1 Neurotensin modulation of pre- and post-synaptic D2 receptors. Relevance for the 
control of striatopallidal GABAergic projections 
As stated above, the motor deficits that characterize Parkinson’s disease are associated to an 
imbalance on the functional activity of the “direct”–“indirect” circuits in favor of the 
“indirect pathway”, i.e. reduced activity in the “direct pathway” and/or increased activity 
in the “indirect pathway” (Obeso et al., 2000; 2008). Several lines of evidence indicate that 
neurotensin is co-localized and co-distributed with dopamine neurons of the basal ganglia, 
including the somatodendritic complex and axon terminals of various neuronal elements in 
the substantia nigra and striatum. This close anatomical relationship, reinforces functional 
findings demonstrating the existence of reciprocal modulations between neurotensinergic 
and dopaminergic systems in these brain areas (Hökfelt et al., 1984; Nemeroff and Cain, 
1985; Blaha et al., 1990; Castel et al., 1994; Tanganelli et al., 1994; Rostène et al., 1997; 
Werkman et al., 2000). Intensive animal studies have well documented that neurotensin, in 
addition to its direct excitatory effects on dopamine neurons, significantly modulates D2 
auto- and hetero-receptors functions through the activation of its high-affinity NTS1 receptor 
(Kalivas and Duffy, 1990; Werkman et al., 2000; Binder et al., 2001). The regulation of 
dopaminergic transmission, especially at the level of nigrostriatal and mesocorticolimbic 
dopamine pathways, by neurotensin (Kitabgy et al., 1989; Deutch and Zahm, 1992) is mainly 
due to an antagonistic action of the activated NTS1 receptor on D2 receptor recognition and 
signaling. In the striatum, neurotensin has been shown to reduce the affinity of D2 agonist 
binding sites and their transduction signals through a receptor-receptor interaction at both 
pre- and post-synaptic levels (Agnati et al., 1983; von Euler and Fuxe 1987; Shibata et al., 
1987; Da-Silva et al., 1989; Fuxe et al., 1992 a,b). In particular, neurotensin by increasing the 
Kd value of D2 receptor agonist binding, significantly decreases the affinity of D2 receptors 
for endogenous dopamine and dopamine receptor agonists. The neurotensin-induced 
reduction of D2 receptor agonist affinity has been demonstrated both in sections and in 
membrane preparations. The presence at the cellular level of NTS1 and D2 receptors in the 
same axon terminals and dendrites (Delle Donne et al., 2004), together with the 
demonstrated antagonistic intramembrane NTS1/D2 receptor–receptor interactions using 
biochemical radioligand binding analysis in striatal membranes (Agnati  et al., 1983; von 
Euler and Fuxe 1987; Tanganelli et al., 1989; Fuxe et al., 1992b; Li et al., 1995; Diaz-Cabiale et 
al., 2002; Antonelli et al., 2007), give indirect evidence for the existence of NTS1/D2 receptor 
heteromerization. By using intrastriatal monoprobe microdialysis and measuring dopamine 
release from striatal terminals, in vivo evidence has been obtained that the neurotensin/D2 
antagonistic receptor–receptor interaction exists at the pre-junctional level in striatal 
dopamine transmission. This study demonstrate that, as expected, intrastriatal perfusion 
with the preferential dopamine D2 receptor agonist pergolide decreased local dopamine 
outflow, an effect which reflects a stimulation of terminal D2 auto-receptors causing the 
inhibition of striatal dopamine outflow. Interestingly, when neurotensin was co-perfused at 
a low nanomolar threshold concentration, together with pergolide, the inhibitory effect of 
the preferential dopamine D2 receptor agonist on dopamine release is fully abolished as 
measured in the striatum of awake unrestrained rats. This provides a functional in vivo 
correlate to the binding results indicating the existence of antagonistic neurotensin/D2 
receptor–receptor interactions previously shown in neostriatal membranes and sections. A 
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possible direct interaction between D2 and NTS1 receptors with the formation of heteromers 
has also been considered by Jomphe et al. (2006) as one of the possible, but not the exclusive, 
mechanisms underlying the functional control of striatal dopamine D2-mediated 
transmission by neurotensin.  
Biochemical and functional evidence suggests the existence of an antagonistic NTS1/D2 
receptor-receptor interaction in rat neostriatum also at the post-synaptic level (Fuxe et al., 
1992a; Ferraro et al., 1997). Post-synaptic D2 receptors in the neostriatum exist 
predominantly on medium sized GABAergic neurons of the “indirect pathway”, which 
project to the globus pallidus and exert an inhibitory influence on striopallidal GABA 
transmission (Reid et al., 1990; Ferre’ et al., 1993). Converging evidence suggests that the 
behavioural catalepsy associated with blockade of striatal D2 receptors is mediated by 
increased striopallidal GABA transmission, which leads to a decrease in thalamocortical 
motor drive (Drew et al., 1990; Osborne et al., 1994). Neurochemical findings, obtained 
employing in vivo dual-probe microdialysis technique, whereby one probe was implanted 
into the striatum and the other into the ipsilateral globus pallidus, demonstrated that 
intrastriatal perfusion with D2 agonists inhibits striopallidal GABA release (Reid et al., 1990; 
Ferre’ et al., 1993). On the contrary, D2 receptor antagonists enhance striopallidal GABA 
release (Drew et al., 1990). Interestingly, intrastriatal co-perfusion of neurotensin, at a 
concentration by itself ineffective on pallidal extracellular GABA levels, in combination with 
pergolide, fully antagonizes the inhibitory effects of the preferential D2 agonist on pallidal 
GABA release. The presence in the perfusate medium of the selective neurotensin receptor 
antagonist SR48692 removes the antagonistic effect of neurotensin, thus restoring the 
pergolide-induced inhibition of pallidal GABA levels. It is worth noting that higher 
concentrations of neurotensin, via a direct activation of NTS1 receptor subtypes, significantly 
increase pallidal GABA outflow. SR48692 fully counteracts the facilitatory effects of 
neurotensin, indicating the involvement of NTS1 receptors located on striopallidal 
GABAergic neurons in this effect. In view of the evidence showing that behavioural 
catalepsy in rodents and akinesia in humans are mediated by an increased striopallidal 
GABA transmission (Scheel-Kruger, 1986; Drew et al., 1990; Osborne et al., 1994), these 
findings suggest that the cataleptic profile of neurotensin (Shibata et al., 1987; Da-Silva et al., 
1989) may be explained by its ability to influence neurotransmission in the “indirect 
pathway”. In particular, the cataleptic action of neurotensin may be in part related to an 
enhancement of endogenous neurotensin signalling and in part to a reduction of post-
synaptic D2 receptors affinity. The existence of this intramembrane antagonistic 
neurotensin/D2 receptor interaction is also supported by the finding that haloperidol-
induced catalepsy is associated with an increase in pallidal GABA release (Drew et al., 1990; 
Osborne et al., 1994). Briefly, neurotensin-induced increase of pallidal GABA release and the 
consequent activation of striopallidal GABA transmission, may represent the neurochemical 
substrate to explain the behavioural data indicating that the activation of striatal NTS1 
receptors reduces motor activity (Poncelet et al., 1994).  
5.2 Neurotensin modulation of striatal pre- and post-synaptic D2 receptors. Functional 
consequences on the activity of the “indirect pathway” 
As previously reported, in the “indirect pathway” the striatopallidal GABAergic projection 
corresponds to the first neuron of the trisynaptic connection that projects to the substantia 
nigra pars reticulata. The GABAergic projection from the globus pallidus to the subthalamic 
nucleus represents the second neuron whereas the subthalamic nucleus glutamatergic cells 
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projecting terminals to the substantia nigra pars reticulata and collaterals to the internal part 
of the globus pallidus, the third one. Thus, changes in the activation of striatopallidal GABA 
neurons lead to modifications of the activity of subthalamic nucleus glutamate neurons and 
consequent variations in substantia nigra pars reticulata and pallidal glutamate release. In 
view of the above data and to analyze the functional relevance of striatal NTS1 receptor 
activation on the activity of the “indirect pathway”, a dual-probe microdialysis analysis was 
planed. One probe was implanted into the striatum and the other one in the ipsilateral 
globus pallidus of the awake rat; the effects of neurotensin on striatal and pallidal glutamate 
levels were then measured. In this part of the present section the results coming from these 
microdialysis studies, will be summarized. 
5.2.1 Effects of striatal NTS1 receptor activation on pallidal glutamate levels 
Extracellular pallidal glutamate levels are mainly derived from the collaterals of the 
subthalamic nucleus-substantia nigra pars reticulata neurons (see above). Intrastriatal 
infusion with a high concentration of neurotensin increases striatal and pallidal glutamate as 
well as pallidal GABA levels (see also the above section). All these effects are counteracted 
by the local perfusion with the NTS1 receptor antagonist SR48692. Thus, the intrastriatal 
neurotensin-induced increase of pallidal glutamate levels may be related to a direct 
activation of somatodendritic NTS1 receptors located on the striatopallidal GABA neurons 
or to the antagonistic NTS1/D2 receptor-receptor interaction. The demonstration that the 
striatal neurotensin-induced increase in pallidal glutamate levels is counteracted by the 
intrapallidal perfusion of the GABAA receptor antagonist (-)-bicuculline, suggests that this 
effect is mediated via the activation of striatopallidal neurons. In fact, it seems likely that the 
stimulation of striatal NTS1 receptors, by increasing striatopallidal GABA release, reduces 
the activity of GABAergic neurons projecting from the globus pallidus to the subthalamic 
nucleus, thus increasing pallidal glutamatergic transmission. In other words, this sequence 
of GABA-mediated inhibitory modulations induces a disinhibition of the excitatory 
glutamatergic subthalamic nucleus-substantia nigra pars reticulata efferents which send 
axon collaterals to the globus pallidus (Alexander and Crutcher, 1990). The intrapallidal (-)-
bicuculline perfusion was employed since previous studies demonstrated the role of GABAA 
receptor activation in regulating the pallidal output system toward the subthalamic nucleus 
(Kita, 1992; Amalric et al., 1994). Accordingly, an electrophysiological study (Soltis et al., 
1994) demonstrated that the infusion of bicuculline into subthalamic nucleus increased the 
firing rate of pallidal neurons.  
5.2.2 Effects of NTS1 receptor activation on striatal glutamate levels 
Extracellular striatal glutamate levels are derived in part, from the terminals of cortical and 
thalamic afferents (Sirinathsinghji and Heavens, 1989; Parent and Hazrati, 1995). As 
previously stated, intrastriatal perfusion with neurotensin at a high concentration increases 
striatal glutamate levels and this effect is fully counteracted by SR48692. 
Immunohistochemical studies have shown that in the striatum and nucleus accumbens, 
NTS1 receptors and dopamine D2 receptors are expressed on axon terminals, including the 
glutamatergic ones (Delle Donne et al., 2004). In this context, it seems possible that at least 
two mechanisms might underlay the neurotensin-mediated enhancement of striatal 
glutamate release. The first one may be related to a direct activation of local NTS1 receptors 
expressed on striatal glutamate terminals. The second mechanism implies that the formation 
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of a NTS1/D2 heteromeric receptor complex mainly located on the plasma membrane of 
striatal glutamate terminals, antagonizes the inhibitory D2 receptor mediated signaling 
(see above) on the glutamate terminals, leading to an increase of glutamate release. The 
presence of a functional antagonistic pre-synaptic NTS1/D2 interaction on glutamatergic 
striatal terminals has been demonstrated since a threshold concentration of neurotensin 
counteracts the D2 agonist quinpirole-induced inhibition of K+-evoked striatal glutamate 
levels.  
5.3 Neurochemical studies: concluding remarks 
The analysis of all the above microdialysis results suggests that the over-activity of 
striatopallidal GABA pathway is under the control of NTS1 receptors located both on 
medium size spiny striatal GABAergic neurons and on striatal glutamatergic terminals. The 
mechanisms involved in this control are mainly associated to a direct activation of NTS1 
receptor homomer or to an antagonistic NTS1/D2 receptor-receptor interaction (Figure 3). 
Based on these molecular mechanisms, it might be suggested that the activation of NTS1 
receptors suppresses the inhibitory control mediated by nigrostriatal dopaminergic neurons 
on striatopallidal GABAergic neurons and enhances the excitatory cortico-striatal 
glutamatergic signaling. The final consequence of these combined opposite modulations is 
the hyperactivity of the striatopallidal GABAergic neurons of the “indirect pathway” which 
is considered one of the anomaly responsible for generation of motor parkinsonian 
symptoms (see section 2). Thus, neurotensin receptor antagonists, by counteracting the 
neurotensin-induced hyperactivity of striatopallidal GABAergic neurons, could be useful to 
reduce motor symptoms in Parkinson’s disease patients. 
6. Neurotensin and Parkinson’s disease: biochemical and morphological 
analyses in neuronal cell cultures  
The substantial elevation in extracellular glutamate accompanied by an excessive activation 
of excitatory amino acid receptors generates neuronal cell death (Sonsalla et al., 1998). 
Glutamate has been one of the major focus of research into the excitotoxic basis of 
neurodegenerative diseases (Choi, 1988; Meldrum and Garthwaite, 1990). In vivo and in 
vitro studies have shown that neurotensin significantly increases endogenous glutamate 
outflow in discrete rat brain regions, such as the striatum, globus pallidus, frontal cortex, 
substantia nigra and parabrachial nucleus-ventrobasal thalamus (Sanz et al., 1993; Saleh, 
1997; Ferraro et al., 1998, 2000, 2001). These findings suggest that neurotensin may play a 
relevant role in reinforcing the effects exerted by glutamate on a variety of central nervous 
system functions. In particular, the observations that neurotensin amplifies glutamate levels 
and antagonizes the dopamine D2 receptor-mediated inhibition of dopamine transmission in 
the basal ganglia (Fuxe et al., 1992 a,b), indicate that neurotensin may contribute to enhance 
the firing rate and energy demands in the nerve cells. In this context, as illustrated in section 
4, a putative role of neurotensin in the development of Parkinson’s disease, has been 
suggested (Fernandez et al., 1995, 1996; Tanji et al., 1999; Schimpff et al., 2001).  
In this paragraph, the effects of neurotensin in modulating the glutamate-induced 
neurodegenerative effects in cultured rat mesencephalic dopaminergic (Antonelli et al., 
2002) and cortical (Antonelli et al., 2004) neurons will be shortly summarized.  
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Fig. 3. Schematic representation of the pre-and postjunctional neurotensin (NT) receptor 
(NTS1) and dopamine (DA) D2 receptor interactions in the striatum taking place in NTS1/D2 
heteromers in balance with excitatory NT receptor homomers (Modified from Ferraro et al., 
2008). 
6.1 Effects of neurotensin on glutamate-induced excitotoxicity in primary cultures of 
mesencephalic neurons 
Biochemical and morphological approaches (Antonelli et al., 2002), provided evidence that 
the neurotoxic effects of glutamate on primary cultures of mesencephalic neurons are 
exacerbated by neurotensin.  
Mesencephalic cell cultures, which contain dopaminergic neurons, express glutamate 
receptors (Meltzer et al., 1997; Yung, 1998; Mateu et al., 2000) as well as functional 
neurotensin receptors (Nalivaiko et al., 1998; Nouel et al., 1999). Thus, this in vitro 
preparation represents a suitable model for testing the influence of neurotensin on 
glutamate-induced neurotoxicity. Measurement of [3H]dopamine uptake in mesencephalic 
cell cultures has been proved a reliable parameter with which to evaluate the metabolic and 
structural integrity of the dopaminergic neurons in culture (Mount et al., 1989; Antonelli et 
al., 2002). In particular, in mesencephalic cell cultures intoxicated with glutamate, a 
reduction of [3H]dopamine uptake, is observed. The exposure of cells to neurotensin 
exacerbates the glutamate-induced neurotoxicity, causing a further reduction of 
[3H]dopamine uptake. Similar results were also obtained by evaluating the vulnerability of 
the mesencephalic cells to glutamate using tyrosine hydroxylase immunoreactivity. The 
tyrosine hydroxylase-immunoreactive cell count allows to quantify dopamine cell survival 
or loss of phenotype (Bowenkamp et al., 1996). As shown in Figure 4, the enhancing action 
of neurotensin on glutamate-induced toxicity in dopaminergic neurons has also been 
demonstrated by the increased disappearance of tyrosine hydroxylase-immunoreactive 
neurons pretreated with glutamate and neurotensin in combination. The selective 
neurotensin receptor antagonist SR48692 counteractes the above-mentioned effects of 
neurotensin, indicating that NTS1 receptor was mainly involved in the neurotensin-induced  
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Fig. 4. Representative photomicrographs of tyrosine hydroxylase-immunoreactive 
mesencephalic cells in culture. A (control) shows a typical culture of tyrosine hydroxylase-
immunoreactive neurons, with long processes and network. B shows a field of tyrosine 
hydroxylase-immunoreactive neurons exposed to 100 µM glutamate for 10 min, in which 
there is an evident neuronal loss (from Antonelli et al., 2002). 
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enhancement of glutamate injury. Since NTS1 receptors are coupled to phospholipase C 
(Cathala and Paupardin-Tritsch, 1997; Trudeau, 2000), the effect of the combination of 
neurotensin with glutamate on [3H]dopamine uptake was also evaluated in the presence of 
the specific protein kinase C inhibitor calphostin C (Kobayashi et al., 1989). The neurotensin-
induced enhancement of glutamate neurotoxicity is completely prevented by calphostin C. 
Thus, it seems possible that the nigral NTS1 receptors located on dopamine cells (Nalivaiko 
et al., 1998) enhance glutamate receptor subtype signaling through a protein kinase C 
activation. This finding suggests that neurotensin-mediated rise of glutamate excitotoxicity 
could be mediated by phosphorylation(s) of receptor-associated protein(s) involved in 
receptor signaling and/or trafficking.  
6.2 Effects of neurotensin in modulating the neuronal activity of NMDA receptor in 
primary cortical cell cultures of rat 
Evidence has been accumulated that the excessive activation of glutamate receptors, 
particularly NMDA receptors, may contribute to the neuronal cell death associated with 
chronic neurodegenerative disorders including Parkinson’s disease and Alzheimer’s 
disease. In this paragraph, the evidence for a functional role of NTS1 receptors in 
modulating the neuronal activity of NMDA receptor in cortical glutamatergic nerve cells, 
will be discussed.  
Accordingly to the above in vivo and in vitro experiments, neurotensin increases basal 
endogenous glutamate release from rat cortical cell cultures. The involvement of NTS1 
receptors in this increase is further supported by the antagonistic effect of SR48692. The 
exposure of cortical cell cultures to NMDA induces a concentration-dependent increase in 
endogenous extracellular glutamate levels, an increase that is enhanced in the presence of a 
sub-threshold concentration of neurotensin. These results indicate that NTS1 receptor 
activation enhances the NMDA-receptor signaling and suggest the existence of facilitatory 
NTS1/NMDA interactions at the membrane level. The lack of a neurotensin-mediated 
enhancement of glutamate outflow in the presence of NMDA receptor blockade further 
supports the hypothesis that neurotensin is a modulator of NMDA receptor function. 
Morphological analysis strengths the above hypothesis since neurotensin, in threshold 
concentration, enhances the glutamate-induced increase in the number of the apoptotic cells 
and such an effect is counteracted by SR48692 (Antonelli et al., 2004). A direct facilitatory 
NTS1/NMDA interaction may therefore produce plastic changes in glutamate transmission 
and, if excessive, produce increases in glutamate-induced excitotoxicity. Under 
physiological conditions such a postulated NTS1/NMDA heteromeric complex may 
modulate metaplasticity which is another main mode of homeostatic plasticity (see Perez-
Otano and Ehlers, 2005), which serves to establish that receptor plasticity may exist in a 
proper working range, avoiding e.g. a dramatic NMDA receptor internalization and 
downregulation.  
At the present, several mechanisms possibly underlying the demonstrated synergistic 
NTS1/NMDA receptor interactions can be hypothesized: i) both receptors are known to 
produce an increase in intracellular Ca++ levels and their co-activation may therefore lead to 
a rapid and robust rise of intracellular Ca++ levels; ii) synergistic NTS1/NMDA effect may 
involve a protein kinase C mediated phosphorylation of the NMDA receptors. It is worth 
noting that the inhibition of the protein kinase C by calphostin C suppresses the NTS1-
mediated enhancement of NMDA-induced increases of extracellular glutamate levels. 
(Antonelli et al., 2004). This finding assumes a particular relevance in view of the 
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demonstration that protein kinase C is likely to be an important regulator of neuronal 
NMDA receptors in vivo. The activation of protein kinase C increases NMDA channel 
opening rate and a rapid delivery of functional NMDA receptors to the cell surface. Thus, 
regulation of neuronal NMDA receptors by protein kinases plays a critical role in synaptic 
transmission and synaptic plasticity of NMDA receptors. Since phospholipase C–protein 
kinase C–inositol triphosphate pathway is the major signal transduction of NTS1 receptors, it 
may be suggested that the existence of a neurotensin-mediated potentiation of NMDA 
receptors involves the activation of protein kinase C. Similarly to the above hypothesis, it 
has been demonstrated that mGluR1 activation potentiates NMDA receptors by an 
activation of protein kinase C (Skeberdis et al., 2001; Matsuyama et al., 2002); iii) it also 
seems possible that NTS1 receptor by forming a receptor heteromer with the NMDA 
receptor (NTS1/NMDA heteromer) may contribute to enhance NMDA receptor signalling 
and its surface expression; iv) a recent paper reported that neurotensin receptor agonists 
robustly increased extracellular concentrations of glycine in the rat prefrontal cortex (Li et 
al., 2010). It is well known that normal NMDA receptor function depends on not only the 
binding of glutamate to the receptor but also the binding of glycine to an allosteric site on 
this receptor. Thus, it could be suggested that neurotensin modulates NMDA receptor 
functions by modulating allosteric glycine activity.  
Taken together, the results obtained in mesencephalic and cortical cell cultures suggest that 
neurotensin receptor antagonists, by counteracting the neurotensin-induced amplification of 
glutamate excitotoxicity could display neuroprotective properties. 
7. Neurotensin receptor blockade in an animal model of Parkinson’s disease 
The postulated neuroprotective properties of neurotensin receptor antagonists are also 
supported by experiments (Ferraro et al., 2008) carried out in a rat model of Parkinson’s 
disease [unilateral nigral 6-hydroxydopamine induced lesion of the nigrostriatal DA 
pathway, hemiparkinson model]. In this study, behavioural and biochemical experiments 
have been performed in control animals and in 6-hydroxydopamine unilaterally lesioned 
rats chronically treated with saline or with the NTS1 receptor antagonist SR48692 from one-
week before until one-week after the lesion. A conventional behavioural assessment using 
apomorphine-induced rotation was performed to quantify the unilateral nigrostriatal lesion-
induced motor asymmetry after ipsilateral 6-hydroxydopamine injection. As expected, in 6-
hydroxydopamine-lesioned rats, but not in control rats, the apomorphine injection 
produced a controlateral turning behaviour that significantly and progressively increased 
from week 1 to the 3rd week following the lesion. However, interestingly, in the SR48692-
treated group, but not in the vehicle-treated group, the apomorphine-induced rotational 
behaviour is significantly reduced at each time of evaluation (day 7, 14 and 21 post lesion). 
Moreover, whereas the treatment stopped 2 weeks before, the effect of the compound 
remains significant. This finding suggests that systemic administration of NTS1 antagonist 
decreased the functional consequence of a partial dopaminergic lesion induced by 
intranigral application of the neurotoxin 6-hydroxydopamine in the rat.  
In view of the above behavioural findings, neurochemical experiments have been carried 
out in control animals and in rats chronically treated with SR48692 or its vehicle from one-
week before until one week after the 6-hydroxydopamine injection. In particular, the 
responsivity to a challenge with NMDA has been assessed. The results obtained from this 
study demonstrate that in 6-hydroxydopamine-lesioned control and vehicle-treated rats, 
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intrastriatal perfusion with NMDA induced a slight increase in glutamate extracellular 
levels that was significantly lower than that observed in sham-operated animals. 
Interestingly, in 6-hydroxydopamine-lesioned rats chronically treated with SR48692, the 
effect of intrastriatal perfusion of NMDA induced an increase in glutamate extracellular 
levels that was significantly higher with respect to that obtained in the group of 6-
hydroxydopamine lesioned rats but still lower to that observed in control rats.  
These neurochemical results are in line with previous microdialysis data indicating that 
dopamine denervation is associated with a reduction of the enhancement of striatal 
glutamate transmission induced by a high micromolar NMDA concentration. Since it has 
been demonstrated that endogenous dopamine in the striatum facilitates strong excitatory 
inputs, the reduction of NMDA-stimulated glutamate levels in lesioned-animals could 
imply a loss of facilitatory dopamine receptor mediated signals. In this view, the 
observation that in rats chronically treated with SR48692 the excitatory response to a 
NMDA stimulus on the striatal glutamatergic transmission is partially restored may 
support a protective action of the NTS1 antagonist against 6-hydroxydopamine-induced 
dopamine neuron degeneration.  
8. Conclusion 
Parkinson's disease is associated to a progressive loss of nigrostriatal dopaminergic neurons. 
The decrease of dopamine levels in the striatum of parkinsonian patients is responsible for 
the main motor disturbances characteristic of the disease such as akinesia, muscular rigidity 
and tremor. The strict interactions between the tridecapeptide neurotensin and the 
dopaminergic systems lead to hypothesize that the peptide could be involved in some 
aspects of Parkinson’s disease. In this context, the present chapter discusses the putative role 
of neurotensin in the development and symptoms of Parkinson’s disease.  
Human studies provide evidence that in the basal ganglia of Parkinson’s disease patients 
there is an increase in neurotensin levels. These changes might be an integral part of the 
pathology rather than a consequence of the dopamine neuron degeneration. In addition, 
neurotensin receptor binding sites, especially in the nigrostriatal dopamine system, are 
reduced in brains of Parkinson’s disease patients and in the basal ganglia of 
hemiparkinsonian rats. This is probably a result of the ongoing degeneration of nigral 
dopamine cells in which the peptide actively participates.  
Based on neurochemical and morphological animals studies, the hypothesis is now 
introduced that the activation of NTS1 receptors by enhancing glutamate release and by 
amplifying the NMDA-mediated glutamate signalling contributes to the degeneration of 
dopaminergic neurons in Parkinson’s disease. In addition, the reduction of the D2 
autoreceptor signaling due to the antagonistic NTS1/D2 receptor-receptor interaction, by 
enhancing the firing rate of dopamine neurons and energy demand may further contribute 
to this degeneration.  
The neurochemical studies have also clearly demonstrated that increased striatal 
neurotensin levels, by leading to an over-activity to the “indirect pathway” in the basal 
ganglia, could also play a role in motor Parkinson’s disease symptoms. 
In closing, in view of the presented results, it could be suggested that NTS1 antagonists, in 
combination with conventional drug treatments, may provide a possible novel therapeutic 
approach for the treatment of neurodegenerative pathologies, especially Parkinson’s 
disease. This hypothesis is supported by studies demonstrating the putative neuroprotective 
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effects of the neurotensin receptor antagonist SR48692 (systemically administered) in an in 
vivo animal model of Parkinson’s disease. However, Mesnage et al. (2004) in an exploratory 
study reported that SR48692 could not improve parkinsonian motor disability. However, in 
this paper the authors reported that the lack of efficacy of NTS1 receptor antagonists could 
be attributed to the low dose used, as demonstrated by the absence of adverse events 
observed in any of the patients tested. In fact, it was concluded that further studies with 
higher doses of neurotensin receptor antagonists are needed.  
Taken together, the reported findings prompt to continue these preclinical studies in order 
to better understand the role of neurotensin in Parkinson’s disease development and 
symptoms. 
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